July 5th, 2012

Devicare announced today that it has signed a licensing agreement with Laboratorios Sanifit , spin- off of the University of the Balearic Islands , which grants the exclusive exploitation rights in a worldwide patent for the preventive control of renal lithiasis .

Renal lithiasis is a chronic disease with a prevalence of 10 % of the population , a recurrence of 60 % at 5 years and 80% in 10 years, and an annual incidence of 1% . It is also a major cause of chronic kidney disease. This disease is characterized by acute painful episodes known as renal colics affecting the quality of life of patients who suffer this disease .

This agreement represents a great opportunity to bring to the market the world’s first medical device for the preventive control of renal lithiasis, but also to initiate collaborations between Devicare, Sanifit Laboratories and the University of the Balearic Islands in order to develop new products in this therapeutic area .